Cytokinetics stock heads into four October heart presentations

Published on 10/04/2026 at 23:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytokinetics stock heads toward four HFSA presentations announced October 2, including late-breaking ACACIA-HCM data. Second-quarter revenue reached USD 28.624 million.

CYTK, US23282W6057, Illustration mit AI erstellt.

Cytokinetics stock (ISIN US23282W6057) was last at USD 65.60 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a daily change of -0.03 percent. On October 2, 2026, Cytokinetics announced four presentations at the Heart Failure Society of America meeting, putting new aficamten data on the near-term calendar.

Four presentations set the schedule

The company plans two oral presentations on October 10 and October 11, followed by two late-breaking clinical research presentations on October 12. The sessions cover ACACIA-HCM results in nonobstructive hypertrophic cardiomyopathy and SEQUOIA-HCM findings on right ventricular function, exercise performance and dosing safety.

The October 12 program is the most consequential date in the announcement because it includes global efficacy results from ACACIA-HCM. Cytokinetics said the company plans to submit a supplemental application for aficamten in nonobstructive hypertrophic cardiomyopathy in Q4 2026, linking the presentations to a regulatory development path.

Revenue beat but losses remain

For the quarter ended June 30, 2026, Cytokinetics reported revenue of USD 28.624 million and an adjusted loss of USD 1.50 per share, according to MarketBeat. Revenue exceeded the USD 17.59 million consensus, while the loss was narrower than the USD 1.63 consensus loss, creating a clear operating comparison despite revenue falling 57.1 percent from the comparable quarter.

The balance sheet also shows the cost of commercialization and development: cash and cash equivalents stood at USD 255.271 million at June 30, 2026, while operating cash flow was negative USD 159.840 million for the quarter. The next clinical data cycle therefore matters alongside the pace at which MYQORZO can build recurring revenue.

Consensus stays above the share price

MarketBeat reported a Moderate Buy consensus based on 18 Buy ratings, one Hold and one Sell, with an average target of USD 106.00. At USD 65.60, that target lies 61.6 percent above the October 2 price, although the consensus is a collection of analyst views rather than a company forecast.

The latest rating split is less uniform than the average suggests. MarketBeat reported on October 4, 2026, that Wall Street Zen lowered Cytokinetics from Hold to Sell, while JPMorgan had raised its target from USD 97.00 to USD 103.00 on August 13, 2026.

Stock remains below its yearly high

Cytokinetics had a market capitalization of USD 8.2 billion and volume of 2,649,872 shares on October 2, 2026. Its 52-week range was USD 54.30 to USD 88.31, leaving the last price USD 22.71 below the yearly high and USD 11.30 above the yearly low.

The stock's market profile now combines a scheduled clinical-data catalyst with a quarterly revenue beat and persistent cash use. For investors, the October presentations offer the next defined test of whether aficamten data can support the company's commercial and regulatory ambitions.